title: The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration.
abstract: Osteogenic agents, such as bone morphogenetic protein-2 (BMP-2), can stimulate the degradation as well as the formation of bone. Hence, they could impair the osteoconductivity of functionalized implant surfaces. We assessed the effects of BMP-2 and its mode of delivery on the osteoconductivity of dental implants with either a naked titanium surface or a calcium-phosphate-coated one. The naked titanium surface bore adsorbed BMP-2, whilst the coated one bore incorporated, adsorbed, or incorporated and adsorbed BMP-2. The implants were inserted into the maxillae of adult miniature pigs. The volume of bone deposited within a defined "osteoconductive" (peri-implant) space, and bone coverage of the implant surface delimiting this space, were estimated morphometrically 1-3 weeks later. After 3 weeks, the volume of bone deposited within the osteoconductive space was highest for coated and uncoated implants bearing no BMP-2, followed by coated implants bearing incorporated BMP-2; it was lowest for coated implants bearing only adsorbed BMP-2. Bone-interface coverage was highest for coated implants bearing no BMP-2, followed by coated implants bearing either incorporated, or incorporated and adsorbed BMP-2; it was lowest for uncoated implants bearing adsorbed BMP-2. Hence, the osteoconductivity of implant surfaces can be significantly modulated by BMP-2 and its mode of delivery.
authors.affiliation: ITI Research Institute for Dental and Skeletal Biology, University of Bern, Murtenstrasse 35, P.O. Box 54, 3010 Bern, Switzerland.
authors.forename: Yuelian
authors.initials: Y
authors.lastname: Liu
authors.forename: Lukas
authors.initials: L
authors.lastname: Enggist
authors.forename: Alexander F
authors.initials: AF
authors.lastname: Kuffer
authors.forename: Daniel
authors.initials: D
authors.lastname: Buser
authors.forename: Ernst B
authors.initials: EB
authors.lastname: Hunziker
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D001861:Bone Regeneration / Q000502:physiology*; D002130:Calcium Phosphates / Q000378:metabolism; D020099:Coated Materials, Biocompatible / Q000737:chemistry / Q000378:metabolism; D003758:Dental Implantation, Endosseous; D015921:Dental Implants; D020007:Implants, Experimental; D008422:Materials Testing; D016348:Osseointegration / Q000502:physiology*; D013499:Surface Properties; D013552:Swine; D014025:Titanium / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D020099:Coated Materials, Biocompatible; D015921:Dental Implants; D016212:Transforming Growth Factor beta; C020243:calcium phosphate; D014025:Titanium